Prenalterol induced a statistically significant increase in cardiac index (from 2.6 + 0.2 to 3.1 0.3 1/ min/m2), with parallel increases in stroke index (from 28 2 to 34 2 mllbeat/m2). Forearm blood flow measurements increased (from 2.9 + 0.5 to 4.1 0.6 ml/min/100 g), while calculated systemic vascular resistance fell, as did pulmonary capillary wedge pressure (from 13.7 + 1.6 to 10.5 + 1.7 mm Hg). The drug did not alter heart rate, arterial pressure, right heart pressures or the frequency of ventricular premature beats. Prenalterol increased plasma renin activity (from 2.9 0.8 to 6.6 ± 1.8 nmol/l/hour), angiotensin II (from 59 ± 12 to 89 ± 22 pmol/1), urinary aldosterone excretion (from 41 ± 10 to 78 ± 34 nmol/day) and plasma insulin (from 10.6 ± 2.2 to 19.8 ± 3.9 mU/1). Circulating catecholamines, cortisol, glucose, glucagon or pancreatic polypeptide did not change. Dose-response studies in five patients showed dose-dependent increments in hemodynamic variables, while hormonal changes plateaued at the second dose level. We conclude that prenalterol infusion augments myocardial contractility, reduces systemic vascular resistance, and stimulates insulin release and the renin-angiotensin-aldosterone system. NO MAJOR ADVANCE in chronic inotropic treatment for heart failure has taken place since the introduction of digitalis, and the place of this drug for patients in sinus rhythm is still uncertain.1 Several drugs have been investigated.2-Reports that a selective 3 , t agonist, prenalterol, improves myocardial function in patients with heart failure are encouraging, especially because the drug may be effective when given by mouth.5 However, available data relate largely to its administration over a period of minutes only
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Methods
The protocol was approved by the hospital's ethical committee. All patients gave informed written consent.
Clinical details of the six patients are summarized in table 1. All had suffered at least one episode of pulmonary edema but had responded to routine treatment. At the time of entrance to the study, their therapy had not changed for at least 3 months. Patient 1 was on perhexilene and disopyramide, which were discontinued 1 week before the study. Abbreviations: D = digoxin; F = furosemide; T =triamterene; HD = hydralazine; P = prazosin; DCM = dilated cardiomyopathy; IHD = ischemic heart disease; LVEF = left ventricular ejection fraction.
The 6-day protocol called for a 2-day "run-in" period, 3 days of prenalterol infusion, and a "run-out" day after the termination of prenalterol therapy. Throughout these days, each patient received a diet of constant sodium (38-45 nmol/day), potassium (51-67 nmol/day) and carbohydrate content. Urine, obtained with an indwelling bladder catheter, was retained as 24-hour collections on ice for electrolyte and hormone analysis. The patients remained semisupine throughout. Blood sampling for hormone and electrolyte measurements and hemodynamic recordings were carried out twice daily at 8:30 a.m. (fasting) and 3:30 p.m. Digoxin and diuretics were administered immediately after the morning recordings, while vasodilator therapy was given both after morning and afternoon recordings. The dose of these medications remained constant for each patient.
Prenalterol Administration
The drug was diluted in 5% dextrose and water and infused intravenously in an incremental fashion at 60, 120 and 240 nmol/min, each rate for 24 hours, beginning at 9:00 a.m. The dextrose solution was administered at 10 ml/hour throughout using an IVAC pump. During run-in and run-out days, 5% dextrose was infused at the same rate (10 ml/hour) through the right atrial port of the Swan Ganz catheter. Patient 6 developed acute gout; consequently, the protocol in this case was shortened to 2 days of prenalterol infusion at 60 and 120 nmol/min each for 24 hours, followed by a runout day.
Hemodynamic Measurements
On the morning of the first study day, a triple-lumen Swan Ganz catheter was inserted under strictly sterile conditions into the pulmonary artery for measurements of right-heart pressures and cardiac output. A Derived hemodynamic variables were calculated as follows. Stroke work index (SWI) = SI x (MAP -PCWP) x 0.0136 (g-m!m2), systemic vascular resistance (SVR) = 80 (MAP -RAP)/CO (dyn-sec-cm-5), pulmonary vascular resistance (PVR) = 80 (MPA -PCWP)/CO (dyn-sec-cm-5), work product = HR x SBP, where SI = stroke index, MAP = mean systemic arterial pressure, PCWP = pulmonary capillary wedge pressure, RAP = mean right atrial pressure, MPA = mean pulmonary artery pressure, and SBPsystolic arterial pressure.
Hormone and Electrolyte Measurements
Arterial samples were drawn at 8:30 a.m. and 3:30 p. m. daily to measure plasma renin activity,6 angiotensin II,' aldosterone,8 cortisol,9 epinephrine and norepinephrine.'0 Fasting plasma glucose (glucose oxidase method) was determined daily at 8:30 a.m., while fasting arterial samples were drawn for measurements of plasma insulin," I glucagon,'2 and pancreatic polypeptide (by radioimmunoassay using a polyethylene glycol separation technique) at 8:30 a.m. on the second run-in day and again at 8:30 a.m. at the completion of the third day of prenalterol infusion. Urine aldosterone13 and cortisol9 excretion were measured in 24-hour collections by radioimmunoassay and competitive protein binding, respectively. Sodium and potassium in plasma, urine and duplicate diets were determined by flame photometry.
Statistical Methods
Repeated-measures analyses of variance were carried out on all variables using program P2V of the BMDP package. The initial hypothesis tested was that no daily variation occurred, and where variables were measured twice daily, no diurnal variation occurred. For indices exhibiting significant daily variation, further comparisons using t tests, with appropriate meansquare-error terms from analysis of variance, were per-formed to determine when these changes occurred. In the case of variables measured twice daily, the interaction of days and time of day was clearly nonsignificant; thus, we could compare the daily mean values for each index. Cardiac index increased significantly, from a pretreatment mean of 2.6 + 0.2 1/min/m2 to 2.9 + 0.2, 3.1 ± 0.3, and 3.0 + 0.2 1/min/m2 on subsequent days of prenalterol infusion, then declined to 2.8 + 0.2 1/min/m2 upon cessation of the drug. Stroke index changes paralleled changes in cardiac index, except that run-out values were sustained higher than control values. Forearm blood flow, as measured directly by strain-gauge plethysmography, increased from a baseline of 2.9 + 0.5 ml/min/100 g of tissue to 4.1 + 0.6 ml/min/ 100 g on the second and third prenalterol days, then declined when the drug was withdrawn. These changes in measured forearm blood flow matched stepwise decrements in calculated systemic vascular resistance. Mean pulmonary artery pressures and right atrial pressures were unchanged, but a statistically significant decline in pulmonary capillary wedge pressure was noted during the lowest rate of prenalterol infusion, and was sustained during the final two study days.
Heart rate and arterial pressure did not increase during prenalterol administration, and the product of rate and systolic pressure therefore remained stable. Systemic vascular resistance declined significantly; the calculated pulmonary vascular resistance did not change.
Comparing data from the run-in day and the final infusion day, prenalterol induced clear-cut increases in stroke work index in all patients, with concomitant decrements or little change in pulmonary capillary wedge pressure ( fig. 3A) receptors exist on the pancreatic ,3 cell, or that prenalterol has sufficient fl2 agonist action to release insulin. Alternatively, prenalterol may primarily increase blood sugar levels, inducing release of endogenous insulin. Although we saw no significant change in glucose, glucagon or pancreatic polypeptide levels, it appears prudent to monitor blood glucose during future long-term studies of prenalterol.
Since insulin reportedly increases myocardial contractility in cardiac failure27 it is interesting to speculate whether the increase in plasma insulin observed in our study contributed to the inotropic effect of prenalterol.
In conclusion, prenalterol infusion in six pationts with heart failure increased cardiac index and stroke index in a dose-response fashion without adversely affecting heart rate, arterial pressure or right-heart pressures. Forearm blood flow rose in a stepwise fashion during the incremental infusion of prenalterol. Activation of the renin-angiotensin-aldosterone axis was observed, and if sustained during long-term prenalterol treatment, could offset, in part, the beneficial hemodynamic effects. Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart
